Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors?

Ann Marie Navar, Hillary M. Mulder, Daniel M. Wojdyla, Eric D. Peterson

Research output: Contribution to journalArticlepeer-review

2 Scopus citations
Original languageEnglish (US)
Article numbere006019
JournalCirculation: Cardiovascular Quality and Outcomes
DOIs
StateAccepted/In press - 2020
Externally publishedYes

Keywords

  • Approval rates
  • PCSK9
  • Utilization

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this